TerminatedPhase 2

T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation

Stopped: Lack of accrual

United States4 participantsStarted 2015-01-21

Plain-language summary

The purpose of this study is to see if giving the patient stem cells their original donor (boost) after removing the T cells (T cell depleted- TCD boost) without further chemotherapy. The investigators want to see if this can improve bone marrow function. This would also improve the patients white blood counts, red blood counts and platelets. This may make the patients chances of improving and surviving better. The investigators will also be looking at the short term side effects and risks of the TCD boost.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. ANC \<1.0x10\^9/L without filgrastim support or any ANC value that requires recurrent support by filgrastim (administered at least once a week).
✓. Plt\<50x10\^9/L
✓. Hb\<8 or PRBC transfusion dependent (once every 2 weeks or more) with reticulocyte count of \< 40x10\^9/L.

What they're measuring

Peripheral Blood Counts Recovery (Response Will be Defined by Stable Blood Counts (ANC>1000, Hb>8 With Absolute Reticulocyte Count>20x10^9/L ,and Plt>50,000) Without Support of Blood Product Transfusions and/or Growth Factors.

Timeframe: 1 year

Trial details

NCT IDNCT02350777

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-10-25

Results submitted2018-04-05

View on ClinicalTrials.gov More Hematopoietic Stem Cell Transplant trials